Iloprost Zentiva Italia (Iloprost)

Iloprost is a synthetic prostacyclin analog that activates IP receptors on vascular smooth‑muscle cells, raising intracellular cAMP levels. This cascade causes vasodilation, inhibits platelet aggregation, and exerts antiproliferative effects on the arterial wall, thereby improving circulation in affected vascular beds.

The specific dose and infusion schedule of Iloprost Zentiva Italia are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosing is individualized and should follow the prescriber’s instructions.

The safety of Iloprost during pregnancy and lactation has not been established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Iloprost belongs to the prostacyclin analog class, offering intravenous delivery and direct vasodilatory effects. Compared with oral endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides rapid hemodynamic improvement but requires infusion equipment and careful monitoring, making it suitable for patients needing acute or intensive therapy.

Iloprost Zentiva Italia should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Iloprost Zentiva Italia is administered intravenously by a healthcare professional. The drug is typically infused over a set period using an infusion pump, with dosage and duration adjusted according to the patient’s clinical response and tolerability.

Serious risks include severe hypotension, pulmonary edema, significant bleeding due to platelet inhibition, thrombocytopenia, arrhythmias, and rare myocardial infarction. Patients should be monitored closely for these events, especially during the initial infusion period.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with uncontrolled severe hypotension, and individuals receiving other prostacyclin analogs without medical supervision. Caution is also advised for patients with active bleeding or severe hepatic impairment.